0001459839-26-000056
SEC filingRevenue grew 11.2% to $52.6M, driving a 31.9% improvement in operating loss to -$5.1M, though cash burn continues as the company invests in commercial expansion.
Revenue for the first quarter of fiscal 2026 increased 11.2% to $52.6 million, compared to $47.3 million in the same period last year. The growth was primarily driven by higher U.S. procedure volumes and expanded adoption in ambulatory surgery centers (ASCs) and office-based labs (OBLs). The company continues to invest in its commercial infrastructure, with a sales force of 89 territory managers and 336 agents, which supports broader market coverage and productivity.
Gross profit rose 11.3% to $41.9 million, yielding a gross margin of 79.8%, essentially stable year-over-year. Management noted that lower product costs were partially offset by higher royalty expenses. The company continues to work with suppliers to improve supply chain efficiency and reduce manufacturing costs, while also optimizing inventory management to support capital efficiency. The stable margin suggests pricing discipline and cost control, though royalty headwinds may persist as new products launch.
Management anticipates continued investment in sales force expansion, product development, and clinical evidence generation to drive adoption. R&D expenses are expected to increase as the company advances next-generation products and regulatory initiatives. The company also highlighted ongoing efforts to improve capital efficiency through optimized inventory management and instrument tray utilization. Key risks include variability in case volumes due to seasonality, reimbursement changes, and sales force turnover, as well as potential foreign exchange headwinds from international operations.